Acute myeloid leukemia trials in China

In China 226 Also abroad 761

226 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Not yet taking people in China
A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
Where
Hangzhou
Age
18 years and over
People
318
Run by
Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT07925190
Phase 2Taking people
Interferon-α Maintenance in Favorable-Risk AML
Where
Beijing
Age
18 years to 70 years
People
30
Run by
Peking University People's Hospital
See details and how to joinNCT07925554
Phase 1/2Not yet taking people in China
Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Where
Nanchang
Age
18 years and over
People
55
Run by
Second Affiliated Hospital of Nanchang University
See details and how to joinNCT07926607
No phaseNot yet taking people in China
Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT
Where
Tianjin
Age
18 years and over
People
169
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07919119
No phaseNot yet taking people in China
MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )
Where
Zhejiang
Age
18 years to 60 years
People
310
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07904884
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Lanzhou, Nanchang, Nanjing, Nanning, Shenyang, Shenzhen, Suzhou, Tijian, Wenzhou, Wuhan, Xiamen, Xi'an, Zhengzhou
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 1Taking people
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
Where
Shanghai
Age
18 years and over
People
122
Run by
Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT07914556
Phase 1/2Not yet taking people in China
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Where
Shenzhen
Age
2 years to 75 years
People
10
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03222674
Phase 1/2Not yet taking people in China
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04033302
Phase 1Not yet taking people in China
Universal 4SCAR7U Targeting CD7-positive Malignancies
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05995028
Phase 1Not yet taking people in China
Universal CAR-T Cells Targeting AML
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05995041
Phase 1Not yet taking people in China
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
Where
Beijing
Age
18 years and over
People
12
Run by
Liping Dou
See details and how to joinNCT07897136
Phase 3Taking people
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Where
Tianjin
Age
55 years to 75 years
People
228
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07132684
Phase 3Taking people
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML
Where
Tianjin
Age
14 years to 75 years
People
788
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07539818
Phase 1Taking people
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Where
Hangzhou
Age
18 years and over
People
36
Run by
Hangzhou Weben Pharma Co., Ltd
See details and how to joinNCT07014449
Phase 1Taking people
Phase I Study of FXS0683 in the Treatment of Blood Tumors
Where
Tianjin
Age
18 years and over
People
228
Run by
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT07616089
Phase 2Taking people
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Where
Beijing
Age
18 years and over
People
50
Run by
Beijing 302 Hospital
See details and how to joinNCT07078591
Phase 1Not yet taking people in China
CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia
Where
Beijing
Age
18 years to 75 years
People
12
Run by
Liping Dou
See details and how to joinNCT07841002
Phase 1Taking people
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
Where
Beijing, Guangdong, Hebei, Hubei
Age
18 years to 75 years
People
168
Run by
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT06820268
Phase 2Taking people
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Where
Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Xiamen, Xi'an, Xuzhou, Zhengzhou
Age
18 years and over
People
130 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06824168
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Lanzhou, Nanchang, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 1Taking people
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Where
Nanchang, Suzhou, Zhengzhou
Age
18 years and over
People
198
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT05641259
Early phase 1Not yet taking people in China
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Where
Shenzhen
Age
18 years to 75 years
People
36
Run by
Grit Biotechnology
See details and how to joinNCT07676006
Phase 2/3Taking people
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Where
Tianjin
Age
18 years to 75 years
People
216
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07255872
Phase 2Enrolling by invitation
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
Where
Guangzhou
Age
18 years and over
People
73
Run by
Guangdong Second Provincial General Hospital
See details and how to joinNCT07813390